Why Marijuana Dispensaries Still Operate Cash-Only—And How Federal Policy Changes Could Fix It

The sight of an ATM inside a cannabis dispensary might seem like a simple convenience, but it reveals a fundamental problem: most marijuana retailers cannot accept credit or debit cards. This cash-only reliance isn’t a choice—it’s a survival mechanism forced by decades of federal restrictions that have essentially locked the cannabis industry out of the mainstream financial system. Understanding why dispensaries remain trapped in this cash economy is essential to grasping how recent regulatory shifts could finally reshape one of America’s largest underground-turned-legitimate industries.

The Financial Trap: Understanding the Cash-Only Reality

At the heart of the cash-only problem lies federal drug policy. Because marijuana remains classified as a Schedule I substance under federal law—alongside heroin and LSD—payment processors and banks treat cannabis businesses as high-risk ventures tied to federal crime. Even in states where cannabis is legal, federal banking regulations create liability concerns for any financial institution that services the industry. The result: most dispensaries cannot process electronic payments, forcing customers to withdraw cash from on-site ATMs before making purchases.

This creates a cascade of business complications. Retailers cannot track spending patterns through payment data, making it harder to understand customer preferences or manage inventory efficiently. More critically, the reliance on physical cash transforms dispensaries into attractive targets for criminals. Theft is rampant at cannabis retailers, with theft rates far exceeding those at traditional retail establishments. Thieves know exactly what they’re looking for—cash, not products—and security costs have become a significant operational expense for legitimate businesses.

The security burden extends beyond immediate theft. Employees working in dispensaries face elevated personal safety risks. High-value cash transactions require constant vigilance and complex security protocols, including surveillance systems, armored vehicle services for cash management, and armed security personnel. These costs directly impact profitability and are passed along to consumers through higher prices.

Federal Drug Classification and Its Hidden Costs

The federal government’s insistence on keeping marijuana in Schedule I creates a second, often invisible financial crisis: extreme tax liability. Under Section 280E of the Internal Revenue Code, businesses involved with Schedule I or II controlled substances cannot deduct ordinary business expenses—rent, salaries, utilities, marketing, or equipment costs. This archaic rule was designed to penalize drug traffickers, but it now applies to legitimate cannabis businesses operating legally under state law.

The impact is staggering. Effective tax rates for cannabis companies soar between 60% and 90%—rates that would bankrupt most industries. According to industry data from GreenWave Advisors, the eight largest multi-state cannabis operators paid only $600 million of the $2.6 billion they owed in federal taxes between 2019 and September 2025. Even profitable companies operate with mounting unpaid tax liabilities hanging over them. One major company’s CEO revealed to NPR that his firm set aside $38 million in 2024 alone to account for potential IRS action, interest, and penalties. That capital could have been deployed toward hiring, research, or expansion—instead, it sits as a defensive cushion against federal audits.

This tax trap creates a perverse incentive structure. The more successful a cannabis business becomes, the larger its tax burden. The more it grows, the greater the IRS risk. Profitability becomes a liability rather than a success metric, which partly explains why cannabis stocks have historically underperformed despite industry growth.

Banking’s Role: Why Financial Institutions Keep Their Distance

The absence of banking services isn’t simply inconvenient—it fundamentally limits business development. Cannabis retailers cannot secure commercial loans because lenders require collateral and loan covenants. If a company’s assets are considered proceeds from federal drug operations, banks face legal exposure by accepting them as collateral. Even banks willing to consider cannabis accounts face compliance nightmares: regulatory uncertainty means they must treat cannabis businesses as perpetual red flags, requiring constant documentation and risk assessment.

The cash-only model also prevents cannabis companies from accessing supply chain financing, equipment leasing, or other standard business tools that legitimate enterprises take for granted. When a dispensary needs to restock inventory or upgrade its point-of-sale system, it cannot simply finance the purchase. Everything must be paid in cash, limiting operational flexibility and innovation. This puts cannabis retailers at a structural disadvantage compared to other consumer-facing businesses.

Furthermore, the inability to accept electronic payments damages customer experience. Many consumers prefer card payments for security, convenience, and reward points. Cannabis retailers lose these customers to black market alternatives, which have increasingly sophisticated payment systems. The federal restrictions thus inadvertently protect the illegal cannabis market while handicapping legal businesses.

Trump’s Regulatory Shift: From Schedule I to Schedule III

In December 2024, President Trump issued an executive order directing the Department of Justice to reclassify marijuana from Schedule I to Schedule III of the Controlled Substances Act. This move does not legalize recreational cannabis nationwide, nor does it resolve every regulatory problem facing the industry. However, it addresses the core legal bottleneck that has confined a $30 billion industry to the financial margins.

Reclassifying marijuana to Schedule III would immediately resolve the Section 280E tax trap. Suddenly, cannabis companies could deduct standard business expenses like rent, salaries, and operational costs—bringing their effective tax rates in line with other industries rather than maintaining the punitive 60-90% burden. The estimated cumulative relief across the industry could reach billions of dollars, freeing capital for legitimate business expansion.

More importantly, reclassification would open the door to mainstream banking. With marijuana in Schedule III rather than Schedule I, banks and payment processors could serve cannabis businesses without the same level of federal legal exposure. They would still need to implement compliance protocols and could still face scrutiny, but the fundamental legal barrier would diminish. This regulatory change could catalyze rapid transformation in how cannabis businesses operate.

Tax Burden Meets Security Challenges

The potential benefits of reclassification extend across multiple business dimensions simultaneously. Consider the typical cannabis retailer: currently, it operates with extreme tax liability, cannot access loans, must maintain significant security infrastructure due to cash holdings, and cannot accept electronic payments. Reclassification alone would not eliminate all these problems—banks would still need time to develop compliant account structures, and cannabis would remain illegal to transport across state lines, limiting national business expansion.

However, the cascade effects matter. If cannabis companies could suddenly deduct business expenses, the $38 million set aside for tax contingencies could be redirected to real security improvements, training, or community investment. If payment processors began accepting cannabis retailers, the security burden from high cash volumes would decrease, making employees safer and reducing operational costs. These improvements would strengthen business fundamentals and improve industry legitimacy.

The challenge is that regulatory change is only half the battle. Previous administrations promised similar reforms. The Biden administration initiated a rescheduling process that ultimately stalled in bureaucracy. Trump’s order still requires implementation by federal agencies and could face legal challenges from opponents. Implementation timelines remain uncertain, and state-level complications persist—cannabis remains a patchwork of conflicting state and federal laws.

The Investment Question: Will Change Actually Stick?

Despite Trump’s executive order, cannabis stocks did not rally. The AdvisorShares Pure US Cannabis ETF declined 27% on the day the order was signed and continued to decline afterward. Part of this reaction reflects normal profit-taking after a long advance of prices, but it also signals deeper investor skepticism. The industry has endured repeated disappointments: promising policy announcements followed by Congressional stalling, regulatory flip-flops between administrations, and endless compliance complications.

Investors have learned to be cautious. Previous rescheduling initiatives have foundered in bureaucratic processes. Legal challenges from various constituencies could delay or derail implementation. Even if reclassification proceeds, banks may move slowly in adopting cannabis-friendly policies due to reputational concerns or compliance uncertainty.

However, there are genuine reasons to believe this moment differs from previous failed attempts. Trump’s administration has already demonstrated a pattern of pushing through regulatory changes in previously untouchable sectors. In July 2024, the administration enacted the GENIUS Act, establishing the first comprehensive federal regulatory framework for cryptocurrency—a sector that, like cannabis, had long struggled to access banking and capital markets. The administration has similarly prioritized research into psychedelics, with the FDA commissioner designating it a “top priority” and the Department of Veterans Affairs conducting clinical trials on psilocybin treatments for veterans.

These parallel initiatives suggest an administration willing to challenge entrenched regulatory positions and navigate contentious industries toward legitimacy.

A Legitimized Industry Emerges

The raw numbers underscore how substantial the cannabis industry has become. Colorado alone exceeded $1 billion in marijuana sales throughout 2025, generating nearly $200 million in state tax revenue—more than many states collect from alcohol taxes. The industry now supports over 400,000 jobs across nearly 15,000 licensed dispensaries nationwide. These are functioning businesses serving millions of customers, generating tax revenue, and creating employment.

Yet this legitimate industry remains trapped by regulatory frameworks originally designed for illicit drug enforcement. Dispensary operators are not criminals—they are entrepreneurs running legal businesses in their jurisdictions. The cash-only requirement, the tax penalties, the banking exclusion, and the security burdens all stem from federal classifications that no longer match commercial reality.

When federal policy finally aligns with state law and business reality, the transformation could be dramatic. Access to banking would modernize operations. Tax relief would enable investment and hiring. Legitimate capital markets could open, allowing cannabis businesses to raise funds through standard channels rather than relying on high-risk equity investors. The industry would shift from survival mode to growth mode, accelerating consolidation, innovation, and mainstream acceptance.

The Path Forward

Trump’s executive order represents a significant structural shift, though not an instant solution. Implementation timelines remain uncertain, legal challenges may emerge, and state-level complications will persist. Interstate commerce restrictions will likely remain in place regardless of Schedule III status. These limitations matter.

However, underestimating this administration’s willingness to advance regulatory change in previously taboo sectors has not proven wise. An industry of 400,000 employees, $30 billion in sales, and growing mainstream legitimacy is too substantial to ignore. The gap between federal law and business reality grows more untenable each year. Whether driven by genuine regulatory philosophy or political calculation, the momentum toward normalizing cannabis appears to have shifted. Dispensaries may not abandon cash registers entirely for years, but the financial mechanisms that have forced their hand could finally begin to change.